Data for PGD2 and other lipid mediator changes in mouse adipose associated with administration of an oral inhibitor of H-PGDS (HQL-79) (Study ST000593)
(Analysis AN000909)Values for each metabolite have been scaled by dividing by the mean across all factors Run Hierarchial cluster analysis on this study | Run Heatmap cluster analysis on this study| Metabolite | F1 | F2 |
|---|---|---|
| 11(12)-EpETre EA | NA | NA |
| 15-HETE EA | NA | NA |
| 1-AG | 0.7411 | 1.2589 |
| 1-LG | 0.8409 | 1.1591 |
| 1-OG | 0.8987 | 1.1013 |
| 2-AG | 0.7056 | 1.2944 |
| 2-LG | 0.7752 | 1.2248 |
| 2-OG | 0.7675 | 1.2325 |
| AEA | 0.8639 | 1.1361 |
| aLEA | 0.9209 | 1.0791 |
| DEA | 0.8921 | 1.1079 |
| DHEA | 0.9054 | 1.0946 |
| Dihomo GLA EA | 0.8810 | 1.1190 |
| LEA | 0.9463 | 1.0537 |
| NA-Gly | NA | NA |
| NO-Gly | 0.9296 | 1.0704 |
| OEA | 0.9161 | 1.0839 |
| PEA | 0.9510 | 1.0490 |
| PGD2 EA | NA | NA |
| PGE2 1G | NA | NA |
| PGE2 EA | NA | NA |
| PGF2a 1G | NA | NA |
| PGF2a EA | 0.9839 | 1.0161 |
| SEA | 0.9280 | 1.0720 |
Factors:
| F1 | Treatment:HQL-79 |
| F2 | Treatment:Vehicle |
